Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stock Watch: One Acquisition Does Not Make A Biotech M&A Boom

Pfizer’s Pandemic Success Finally Prompts A Transaction

Executive Summary

Another blow-out quarter from Pfizer provided the impetus for an acquisition. But the history of recent commercial-stage biotech transactions and the risky nature of all early-stage companies suggest that the floodgates will not burst open.

You may also be interested in...



Stock Watch: Spanners In The Works For Q4 Results

While the implications of the US Inflation Reduction Act are the focus of the sector’s concern this year, another regulatory development will impact earnings sooner.

Pfizer On Paxlovid: "There's Still A Long Way To Go"

Access to the COVID-19 treatment is broadening, but Pfizer says there is still work to do when it comes to getting the antiviral to patients quickly.

Stock Watch: Pfizer Caught Between The Pandemic And The Recovery

The pandemic is bad for Pfizer’s hospital products and traditional vaccine sales – but recovery is less good for Comirnaty and Paxlovid. Were investors right to be underwhelmed by Pfizer’s 2022 projections?

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146385

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel